ERECTILE DYSFUNCTION DRUGS ASSOCIATED WITH MELANOMA

摘要

Phosphodiesterase type 5 (PDE5), the target of oral erectile dysfunction drugs, is part of a signalling pathway that is implicated in the development of malignant melanoma. Now, a large Swedish population-based study, published in JAMA (2015;313(24):2449-2455), has identified a modest but statistically significant increased risk of malignant melanoma in men who have used PDE5 inhibitors, with a multivariate-adjusted odds ratio of 1.21 (95% confidence interval 1.08-1.36) versus non-use.